NightHawk Biosciences (NYSE:NHWK) Shares Cross Below 200 Day Moving Average of $2.60

NightHawk Biosciences, Inc. (NYSE:NHWKGet Rating)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.60 and traded as low as $2.27. NightHawk Biosciences shares last traded at $2.29, with a volume of 58,792 shares trading hands.

NightHawk Biosciences Trading Down 1.3 %

The stock has a 50 day moving average of $2.57 and a 200-day moving average of $2.60. The company has a market capitalization of $58.74 million, a P/E ratio of -1.61 and a beta of 0.28.

NightHawk Biosciences (NYSE:NHWKGet Rating) last announced its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.14. The company had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.30 million. NightHawk Biosciences had a negative return on equity of 30.28% and a negative net margin of 1,995.52%. As a group, sell-side analysts expect that NightHawk Biosciences, Inc. will post -1.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NightHawk Biosciences stock. Wolverine Trading LLC purchased a new position in NightHawk Biosciences, Inc. (NYSE:NHWKGet Rating) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 10,109 shares of the biopharmaceutical company’s stock, valued at approximately $33,000. 18.12% of the stock is currently owned by institutional investors.

NightHawk Biosciences Company Profile

(Get Rating)

NightHawk Biosciences, Inc, an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for NightHawk Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NightHawk Biosciences and related companies with's FREE daily email newsletter.